<SEC-DOCUMENT>0001213900-21-010996.txt : 20210223
<SEC-HEADER>0001213900-21-010996.hdr.sgml : 20210223
<ACCEPTANCE-DATETIME>20210223081209
ACCESSION NUMBER:		0001213900-21-010996
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210223
DATE AS OF CHANGE:		20210223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		21663175

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea136246-8k_neuromedtech.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):
<B>February 23, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-54716</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer <BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7599 Anagram Dr., Eden Prairie, MN 55344</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>952-426-1383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s former name or former
address, if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center; text-indent: 4.15pt"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">N/A</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging Growth Company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 8.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2021, NeuroOne Medical
Technologies Corporation (the &ldquo;<B><I>Company</I></B>&rdquo;) issued a press release announcing that the Company met the first
performance milestone pursuant to the distribution and development agreement, dated as of July 20, 2020, with Zimmer, Inc. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item&nbsp;9.01. </B>&nbsp;<B>Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d)&nbsp; Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><A HREF="ea136246ex99-1_neuromed.htm"><FONT STYLE="font-size: 10pt">Press Release dated February 23, 2021.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;1&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR>
    <TD><FONT STYLE="font-size: 10pt">Dated: February 23, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ David Rosa</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">David Rosa</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea136246ex99-1_neuromed.htm
<DESCRIPTION>PRESS RELEASE DATED FEBRUARY 23, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation Announces Successful Completion of First</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Performance
Milestone in Zimmer Biomet Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eden
Prairie, MN &ndash; February 23, 2021&ndash;</B> NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company),
a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological
disorders, announces today that it has successfully met the first performance milestone in the distribution and development agreement
that was signed with Zimmer Biomet on July 20, 2020. In addition to acquiring the exclusive global distribution rights to NeuroOne&rsquo;s
Evo&trade; (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone
payments if certain events were met within a specified time frame.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dave
Rosa, President and CEO, NeuroOne, says, &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is quite pleased to meet this development milestone. Coupled with the announcement of our recent financing, we are confident
that our partnership with Zimmer Biomet and the progress in our sEEG program position the Company well to offer a unique full
complement of brain recording diagnostic technology in 2021 and beyond.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">NeuroOne
announced on January 15, 2021, the closing of a $12.5 Million Private Placement with certain institutional investors with the
intent to use the proceeds for a proposed Nasdaq uplisting, acceleration of research and development efforts, a potential second
commercial product launch in 2021 pending regulatory clearance, and other general corporate purposes.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">NeuroOne
received FDA clearance for its Evo cortical technology in November 2019. </FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company
began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative
tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson&rsquo;s
disease, epilepsy and pain management due to failed back surgery procedures.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NeuroOne</B><BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition
solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson&rsquo;s disease,
dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve
patient outcomes and reduce procedural costs. For more information, visit <U>https://www.n1mtc.com</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B><BR>
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information
contained in this presentation may be a forward-looking statement that reflects NeuroOne&rsquo;s current views about future events
and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
In some cases, you can identify forward-looking statements by the words &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;objective,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;target,&rdquo; &ldquo;seek,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or the negative of these terms, or other comparable terminology intended to identify statements about
the future. Forward-looking statements may include statements regarding the potential uplisting on the Nasdaq Stock Market, the
timing of submission of our second 510(k) application, the receipt of regulatory clearance, the timingand extent of product launch
and commercialization of the technology (including the targeted product launch in 2021), the use of proceeds from the private
placement, business strategy, market size, potential growth opportunities, plans for product applications and product development,
future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have
a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts
and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results
may be materially different from what we expect due to factors largely outside our control, including risks that the partnership
with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; risks that our sEEG electrodes
may not be ready for commercialization in a timely manner or at all; risks that our technology will not perform as expected based
on results of our pre-clinical and clinical trials, our ability to raise additional funds, uncertainties inherent in the development
process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential
of the markets for our technology, clinical trial patient enrollment, the results of clinical trials, our ability to protect our
intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading &ldquo;Risk
Factors&rdquo; in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date
of this press release and NeuroOne undertakes no obligation to revise or update any forward-looking statements for any reason,
even if new information becomes available in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kelly
Novak</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perspective
Communications<BR>
kellyn@n1mtc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Caution:
Federal law restricts this device to sale by or on the order of a physician&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOURCE:
</B>NeuroOne Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W 4<# 2(  A$! Q$!_\0
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MCXF_8]_X*3^._!GCR\UCQ+^SEXK\"_">?Q#X>B>6[N_AYJ][8:M#<^._"5N
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MD9%PB2EBNU5_0S_@HE_R8W^U)_V1WQ;_ .D8K\"?^"#&/^&J_BSG_HW>Y_\
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M:)I]Q#K/AN*>:XFEW'3='UF'1;5(Q#%#I^F6-ND6Y&=OYE/VV_\ D^G]IO\
M[./U[_T^:92A'6S2>JMUZCD[I-773\#^\-!^[7NVP#))Y)49R0 >2!R #QD8
MKQ/]I#6];\*_ 7XV^*?#>J7.B>(- ^$WCO6M"UFQ$1O]*UC2/#>J7FG:A:B[
MBNK/SK2Y$<T0FM949T F25 JK[<GW%_W5_D*^?OVL/\ DV7]H/\ [(I\3O\
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M&Y7BL?@XXK$XS&3R['99.A[1TJ^/Q.*KJ%2%>=.=*-9TH5*2<*4).7-]L?\
M!2G_ (*9?#'_ ()Z_#S1KS4M*/Q!^,OCU-07X8?"BSU"WT]]5BTJ.*+4/%WB
MS4"MS<:!X%T:]N;:WO=1CM+C4-2O,Z7HMM>7'VAK;^+WX_?\%5/V^OVC=4U&
M]\9_M&^-/ ^@7<L\MKX ^"6JZO\ !_P-I5G<%R--:+P9JVG>*?$5K#%*RM)X
MX\5>*WN)44SPHFU8N;_X*3_M :W^TO\ MN?M ?$O4]1NKO2-/\=:K\.O 5G/
M<2RVFA^ OAS=3^%/#^G:;;R/-%:PW;V%_P"*-0D@>&.]U_Q+JM\(2\^ZH/V
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M_))OAE_V3WP1_P"HMI%?R#?\%M/^3X?BA_V2#X9_^F;Q'7]?/P=_Y)-\,O\
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M^8QX?IX;#8W'X[$PH+&R^K99'#RQ%*A2E.G'VE18RF^>I4Y*4*<YR4HJ:?\
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MZQ*QR+LRG/F!V^[D_O%8GAC\VU23P,X( ]/\G6S93:VS*Q(:"#& <  G!Y
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
